{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:18:28Z","timestamp":1790713108590,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41397-025-00389-8","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:49:15Z","timestamp":1761673755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomic biomarkers of liver toxicity risk from UK Biobank data"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3401-9685","authenticated-orcid":false,"given":"Anna","family":"Shteto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4372-0424","authenticated-orcid":false,"given":"Jawad","family":"Boulahfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8927-5923","authenticated-orcid":false,"given":"Adrien","family":"Etcheto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9937-1416","authenticated-orcid":false,"given":"Yann","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2159-5541","authenticated-orcid":false,"given":"Martin","family":"Kindermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0104-3197","authenticated-orcid":false,"given":"Frederic","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8824-9502","authenticated-orcid":false,"given":"Federico","family":"Goodsaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"389_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1377\/hlthaff.2017.1624","volume":"37","author":"G Ginsburg","year":"2018","unstructured":"Ginsburg G, Phillips K. Precision medicine: from science to value. Health Aff. 2018;37:694\u2013701. https:\/\/doi.org\/10.1377\/hlthaff.2017.1624.","journal-title":"Health Aff"},{"key":"389_CR2","doi-asserted-by":"publisher","first-page":"E105","DOI":"10.1208\/aapsj0901010","volume":"9","author":"F Goodsaid","year":"2007","unstructured":"Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 2007;9:E105\u20138. https:\/\/doi.org\/10.1208\/aapsj0901010.","journal-title":"AAPS J"},{"key":"389_CR3","unstructured":"Tucker N, Sava J. FDA\u2019s ODAC Votes Yes to Requiring Randomized Data for Future PI3Ki Approvals in Hematologic Cancers. https:\/\/www.targetedonc.com\/view\/fda-s-odac-votes-for-requiring-randomized-data-to-support-future-pi3k-inhibitor-approvals."},{"key":"389_CR4","unstructured":"FDA briefing document. Oncologic Drugs Advisory Committee meeting. April 21, 2022. Phosphatidylinositol 3-kinase (PI3K) inhibitors in hematologic malignancies. https:\/\/fda.report\/media\/157762\/ODAC-20220421-Backgrounder-FDA.pdf."},{"key":"389_CR5","unstructured":"Optimus Project. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus."},{"key":"389_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41573-019-0048-x","volume":"19","author":"RJ Weaver","year":"2020","unstructured":"Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldring CE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov. 2020;19:131\u201348. https:\/\/doi.org\/10.1038\/s41573-019-0048-x.","journal-title":"Nat Rev Drug Discov"},{"key":"389_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.yrtph.2018.01.018","volume":"94","author":"N George","year":"2018","unstructured":"George N, Chen M, Yuen N, Hunt CM, Suzuki A. Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regul Toxicol Pharmacol. 2018;94:101\u20137. https:\/\/doi.org\/10.1016\/j.yrtph.2018.01.018.","journal-title":"Regul Toxicol Pharmacol"},{"key":"389_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3748\/wjg.v13.i3.329","volume":"13","author":"R Andrade","year":"2007","unstructured":"Andrade R, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega M, Lucena M. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol. 2007;13:329\u201340. https:\/\/doi.org\/10.3748\/wjg.v13.i3.329.","journal-title":"World J Gastroenterol"},{"key":"389_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jceh.2012.05.002","volume":"2","author":"H Devarbhavi","year":"2012","unstructured":"Devarbhavi H. An update on drug-induced liver injury. J Clin Exp Hepatol. 2012;2:247\u201359. https:\/\/doi.org\/10.1016\/j.jceh.2012.05.002.","journal-title":"J Clin Exp Hepatol"},{"key":"389_CR10","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.3390\/ijms23116049","volume":"23","author":"S Weber","year":"2022","unstructured":"Weber S, Gerbes AL. Challenges and future of drug-induced liver injury research laboratory tests. Int J Mol Sci. 2022;23:6049 https:\/\/doi.org\/10.3390\/ijms23116049.","journal-title":"Int J Mol Sci"},{"key":"389_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ng.379","volume":"41","author":"AK Daly","year":"2009","unstructured":"Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe\u2019er I, Floratos A, et al. HLAB* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816\u20139. https:\/\/doi.org\/10.1038\/ng.379.","journal-title":"Nat Genet"},{"key":"389_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1586\/17474124.2014.922871","volume":"8","author":"M Chen","year":"2014","unstructured":"Chen M, Borlak J, Tong W. Toward predictive models for drug-induced liver injury in humans: Are we there yet? Biomark Med. 2014;8:201\u201313. https:\/\/doi.org\/10.1586\/17474124.2014.922871.","journal-title":"Biomark Med"},{"key":"389_CR13","doi-asserted-by":"publisher","unstructured":"Jullian N, Jourdan N, Afshar M. In: Hypothesis generation for scientific discovery. Examples from the use of KEM\u00ae, a rule-based method for multi-objective analysis and optimization. Solvay Pharmaceutical Conferences: Towards Drugs of the Future. 9, 75\u201380. https:\/\/doi.org\/10.3233\/978-1-58603-949-3-75.","DOI":"10.3233\/978-1-58603-949-3-75"},{"key":"389_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliot L, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203\u20139. https:\/\/doi.org\/10.1038\/s41586-018-0579-z.","journal-title":"Nature"},{"key":"389_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10649-4","volume":"10","author":"P Deelen","year":"2019","unstructured":"Deelen P, van Dam S, Herkert J, Karjalainen J, Brugge H, Abbott K, et al. Improving the diagnostic yield of exome- sequencing by predicting gene\u2013phenotype associations using large-scale gene expression analysis. Nat Commun. 2019;10:2837 https:\/\/doi.org\/10.1038\/s41467-019-10649-4.","journal-title":"Nat Commun"},{"key":"389_CR16","doi-asserted-by":"publisher","first-page":"E455","DOI":"10.1073\/pnas.1322563111","volume":"111","author":"O Zuk","year":"2014","unstructured":"Zuk O, Schaffner SF, Samocha K, Do R, Hechter E, Kathiresan S, et al. Searching for missing heritability: designing rare variant association studies. PNAS. 2014;111:E455\u201364. https:\/\/doi.org\/10.1073\/pnas.1322563111.","journal-title":"PNAS"},{"key":"389_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03476-y","volume":"22","author":"V Rampelbergh","year":"2024","unstructured":"Rampelbergh V, Achenbach P, Leslie R, Kindermans M, Parmentier F, Carlier V, et al. First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes: an exploratory analysis of immune biomarkers. BMC Med. 2024;22:259 https:\/\/doi.org\/10.1186\/s12916-024-03476-y.","journal-title":"BMC Med"},{"key":"389_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/aivt.2017.0027","volume":"3","author":"E Gijbels","year":"2017","unstructured":"Gijbels E, Vinken M. An update on adverse outcome pathways leading to liver injury. Appl In Vitro Toxicol. 2017;3:283\u20135. https:\/\/doi.org\/10.1089\/aivt.2017.0027.","journal-title":"Appl In Vitro Toxicol"},{"key":"389_CR19","doi-asserted-by":"publisher","unstructured":"Saarim\u00e4ki L, Fratello M, Pavel A, Korpil\u00e4hde S, Lepp\u00e4nen J, Serra A, et al. A curated gene and biological system annotation of adverse outcome pathways related to human health. Sci Data. 2. https:\/\/doi.org\/10.1038\/s41597-023-02321-w.","DOI":"10.1038\/s41597-023-02321-w"},{"key":"389_CR20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ijc.32932","volume":"147","author":"D Tang","year":"2020","unstructured":"Tang D, Zhao Y, Liu H, Fang X, Yang X, Chen G, et al. Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer. Int J Cancer. 2020;147:1559\u201370. https:\/\/doi.org\/10.1002\/ijc.32932.","journal-title":"Int J Cancer"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.ddstr.2011.04.002","volume":"9","author":"MA Pacanowski","year":"2012","unstructured":"Pacanowski MA, Zineh I. Pharmacogenomic strategies in drug safety. Drug Discov Today: Ther Strateg. 2012;9:e67\u2013e74. https:\/\/doi.org\/10.1016\/j.ddstr.2011.04.002.","journal-title":"Drug Discov Today: Ther Strateg"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00389-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:01:54Z","timestamp":1766516514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-025-00389-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1038\/s41397-025-00389-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7105178\/v1","asserted-by":"object"}]},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An \u201cethics approval and consent to participate statement\u201d is not independently applicable to this paper on the analysis of data from the UK Biobank. The UK Biobank has its own internal ethics approval process and documentation. An independent ethics approval process would not be germane to the database, analyses or results of this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}